Basque Health Service Hands Roche EUR 102 Million Without a Single Competing Bid, for Six Advanced Cancer and Rare Disease Drugs

Standfirst

OSAKIDETZA, the Basque Country's public health service, has awarded Roche Farma a combined EUR 102 093 742.65 across six separate five year supply contracts covering some of its most advanced biologic medicines, from HER2 breast cancer antibodies to a haemophilia treatment and a lymphoma bispecific antibody. Every one of the six contracts was negotiated directly with Roche, without a competitive tender and each drew exactly one bid, Roche's own.

Introduction

Some public procurement stories are about fierce competition between rival bidders. This one is about the opposite: six major contracts, worth over a hundred million euro combined, where the outcome was never really in doubt because only one company could legally supply the medicines in question.

OSAKIDETZA, the Basque public health service, has secured five years of supply for six advanced biologic drugs, spanning oncology, haematology and ophthalmology, all of them Roche originated medicines protected by patent or regulatory exclusivity. Roche Farma won all six, uncontested, through a procedure that never invited competing bids in the first place.

Why This Contract Matters

The medicines covered here treat serious, often life threatening conditions: a pertuzumab and trastuzumab combination and trastuzumab emtansine for HER2 positive breast cancer, obinutuzumab for blood cancers, glofitamab for lymphoma, emicizumab for haemophilia A and faricimab for retinal diseases like wet age related macular degeneration. Securing five years of guaranteed supply for medicines this clinically important is a significant piece of planning for any regional health system.

The procurement route matters too. Because these are patent protected or exclusively supplied biologics, Spanish and EU procurement law allows health authorities to negotiate directly with the sole eligible manufacturer rather than run an open competition that could never produce a genuine alternative bidder. That is standard practice for originator biologics still under exclusivity, but it also means the usual competitive price discovery mechanism simply does not apply here.

Contract Timeline

• Procedure type: Negotiated without prior call for competition, under Directive 2014/24/EU
• All six contracts concluded: 12 August 2026
• Notice dispatched to the Publications Office: 13 August 2026
• Published in the Official Journal, OJ S 156/2026: 14 August 2026
• Contract term per lot: 5 years, no renewals

Contract Overview

OSAKIDETZA ran a negotiated procedure without prior publicity, Spain's route for direct negotiation with a single supplier when no competitive alternative exists, to secure supply of six medicines across six separate lots. Roche Farma, S.A. Unipersonal submitted the only tender for each lot and was awarded all six, for a combined total of EUR 102 093 742.65, roughly 16.7 percent below the procedure's overall estimated value of EUR 122 512 491.18.

Award criteria were nominally based on best price, with the calculation method detailed in the tender specifications, though with only one bidder per lot, the process functioned as a negotiated price agreement rather than genuine competitive bidding.

Key Contract Details

Project Scope

The six lots cover distinct medicines, each addressed in its own five year supply contract:

All six are Roche or Genentech originated biologic medicines. The pertuzumab and trastuzumab combination and trastuzumab emtansine, marketed as Perjeta, Herceptin and Kadcyla, treat HER2 positive breast cancer. Obinutuzumab, marketed as Gazyva, treats certain blood cancers. Glofitamab, marketed as Columvi, is a bispecific antibody used in lymphoma. Emicizumab, marketed as Hemlibra, treats haemophilia A. Faricimab, marketed as Vabysmo, treats retinal conditions including wet age related macular degeneration. Several of these, particularly the more recently approved Vabysmo, Columvi and Hemlibra, remain under patent or regulatory exclusivity with no biosimilar alternative currently available, which is consistent with this tender's sole source structure.

About the Contracting Authority

OSAKIDETZA, the Basque Health Service, is a regional authority based in Vitoria-Gasteiz, active in the health sector. It is the public health system serving Spain's Basque Country, procuring medicines and supplies for its network of hospitals and health centres through its central organisation and pharmacy service.

About the Organisations Involved

OSAKIDETZA - Servicio Vasco de Salud - Organización Central

As covered above, OSAKIDETZA is the buyer for all six contracts, with its pharmacy service, Servicio de Farmacia, handling the procurement directly.

Órgano Administrativo de Recursos Contractuales de la Comunidad Autónoma de Euskadi

The Basque Country's Administrative Body for Contractual Appeals, based in Vitoria-Gasteiz, is named as the review organisation for these contracts, the standard forum for public procurement disputes within the Basque Country's regional administration.

Roche Farma, S.A. Unipersonal

Roche Farma, S.A. Unipersonal, based in Madrid and classified as a large enterprise, won all six lots. It is the Spanish pharmaceutical subsidiary of Roche, the Swiss headquartered global pharmaceutical and diagnostics group and holds the marketing rights in Spain for all six medicines covered by this procurement, each developed and commercialised under Roche's own biologics portfolio.

Procurement Analysis

OSAKIDETZA used a negotiated procedure without prior call for competition, the appropriate route under EU and Spanish procurement law when a contracting authority can demonstrate that only one economic operator is capable of supplying the goods in question, typically because of patent protection or exclusive marketing rights. Each of the six lots drew exactly one tender, Roche's own, confirming that no alternative supplier was invited or available to compete.

Award criteria nominally centred on price, but with a single bidder per lot, this functioned as a negotiation over acceptable pricing terms rather than a competitive process determining a winner among rivals. The combined awarded value coming in roughly 16.7 percent below the overall estimated value suggests OSAKIDETZA secured meaningful price concessions from Roche during that negotiation, even without competing bids to leverage directly.

All six contracts were concluded on the same day, 12 August 2026 and the notice was published just two days later, an unusually prompt turnaround that suggests these six drug contracts were processed and negotiated together as a coordinated package rather than as separate, staggered procurements.

Additional Procurement Facts

• None of the six contracts are financed with EU funds.
• All six lots are confirmed as covered by the Government Procurement Agreement.
• No framework agreement or dynamic purchasing system applies to any of the six contracts.
• Each contract runs a fixed five year term with no renewal options built in.

Market and Industry Perspective

This procurement is a clean illustration of how patent protected biologic medicines create structurally uncompetitive public procurement, regardless of how the tender itself is designed. Regional health systems across the EU regularly face this dynamic: when only one manufacturer holds regulatory exclusivity for a needed medicine, competitive tendering cannot produce genuine price competition and negotiated procedures become the only realistic route to securing supply.

For Roche, this award reinforces its position as a dominant supplier across several high value biologic categories, from oncology to ophthalmology to haematology, within Spain's Basque health system specifically and reflects the broader reality that originator biologics still generate substantial, largely uncontested revenue from public health systems even as biosimilar competition gradually erodes exclusivity in older product categories.

Economic Significance

At a combined EUR 102 093 742.65 over five years, this represents a substantial, recurring commitment of Basque public health spending to a single pharmaceutical supplier, underscoring how concentrated advanced biologic drug spending can become within specific therapeutic categories where patent protection limits the supplier field to one company.

Future Procurement Opportunities

With five year terms and no renewal options, these contracts will need to be retendered around 2031. By then, several of these medicines may face biosimilar competition as patents expire, potentially opening genuine competitive tendering opportunities for alternative suppliers where none currently exist.

Opportunities for Suppliers

Biosimilar manufacturers should treat this notice as a marker of where genuine future competitive opportunity may emerge in the Basque and broader Spanish public health markets, once patent protection on medicines like trastuzumab emtansine, obinutuzumab, glofitamab, emicizumab and faricimab begins to lapse. Currently, however, this specific procurement offers no opening for alternative suppliers.

What Businesses Should Watch

• Patent expiry and biosimilar development timelines for each of the six medicines covered by this procurement.
• Whether other Spanish regional health services run comparable sole source negotiated procurements for the same Roche medicines.
• Broader trends in EU public health spending on advanced biologics as more categories eventually face biosimilar competition.

SpainTenders.com Procurement Intelligence

This notice is a useful reminder that not every large public contract reflects a competitive market and that is not necessarily a procurement failure. When a medicine is protected by patent or regulatory exclusivity, a negotiated, sole source procedure is the legally correct and practically necessary route and the meaningful discount OSAKIDETZA secured below its own estimate suggests genuine negotiating leverage was exercised even without rival bids on the table.

For pharmaceutical companies and market watchers, the real signal in notices like this one is not the absence of competition today, but the trajectory of patent and exclusivity timelines that will eventually open these categories to biosimilar entrants. Firms developing biosimilars for any of these six medicines should treat regional health systems like OSAKIDETZA as future customers to engage with well ahead of patent expiry, since incumbent suppliers with established clinical relationships and negotiated pricing history will not be easily displaced without active preparation.

Strategically, this award also illustrates how originator biologics companies like Roche continue to derive substantial, largely uncontested public sector revenue from categories where exclusivity persists, even as their broader portfolio gradually faces biosimilar erosion elsewhere. Investors and competitors tracking Roche's European public sector exposure should note the scale of a single Spanish regional health system's five year commitment across just six products.

Supplier Takeaways

• All six contracts were awarded through a negotiated procedure without competition, reflecting the patent protected or exclusively marketed status of each medicine involved.
• The combined awarded value came in roughly 16.7 percent below the original estimate, suggesting real negotiating leverage even absent competing bids.
• Each contract runs a fixed five year term with no renewals, meaning a recompete opportunity will arise around 2031, potentially coinciding with biosimilar availability for some products.
• Biosimilar manufacturers have no near term opening in this specific procurement but should monitor patent expiry timelines for future competitive opportunities.
• Regional Spanish health systems regularly run sole source negotiated procurements of this kind for patent protected biologics, a pattern worth understanding for anyone assessing this market.

Key Takeaways

• OSAKIDETZA awarded Roche Farma six separate five year contracts worth a combined EUR 102 093 742.65, covering pertuzumab/trastuzumab, emicizumab, faricimab, glofitamab, obinutuzumab and trastuzumab emtansine.
• Every contract was negotiated directly with Roche without competitive tendering and each lot drew exactly one bid.
• The combined awarded value came in about 16.7 percent below the original EUR 122 512 491.18 estimate.
• All six contracts were signed on the same day, 12 August 2026.
• None of the contracts are financed with EU funds and all are covered by the Government Procurement Agreement.
• Each contract runs a fixed five year term with no renewal options.

Conclusion

There was never any real doubt about who would win these six contracts and that is precisely the point. When medicine is protected by patent exclusivity, public health systems like OSAKIDETZA negotiate rather than compete and the real story lies in how much value they can extract from that negotiation, not in who shows up to bid. On this occasion, the Basque health service walked away with a meaningful discount and five years of secured supply for six of modern medicine's more advanced treatments, even with only one name on every tender.

Source: Tenders Electronic Daily (TED), Contract Award Notice 565980-2026, Official Journal of the European Union, OJ S 156/2026, published on 14 August 2026.